Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • sarah_27_m
    Junior Member
    • Jan 2017
    • 4

    Using DeSeq2 with 16s data, valid parameters

    Hello,

    I am trying to use DeSeq2 in R to analyse differential abundance between 16s samples at OTU level. However I am not sure if the code I am using is valid for what I want to do. Codes comes from the phyloseq tutorial. http://joey711.github.io/phyloseq-ex...ns/DESeq2.html

    My data is 16s data (Illumima MiSeq), collected from birds with different caecal lesion scores (0, 1, 2, 3, 4) and uninfected controls, for each I have <10 biological replicates per group. What I am interested in doing in comparing abundance of OTUs across groups.

    I do as below to load my data into the matrix and then to ensure that I only have two groups (eg. 4 & uninfected) for comparison I remove the other groups using the subset option. Then run the code below.

    My question is, is subsetting like this still allowing the program to take all of the data, even that which isn't being compared, into account?

    Secondly am I struggling to know which parameters to use for this type of data with DeSeq2. Can I simply implement what is done for RnaSeq data here to look for differentially abundant OTUs or is this wrong completely? I am not sure which fitType to use; parametric or local or which test to use; Wald or LRT? Doing comparisons there is not much difference in the data, but would be good to know which is best to use.

    The reason I am using DeSeq2 is because I have a small data set, min of 8 biological replicates, max of 11 biological replicates per group.

    Having read the package manual I am still unclear. http://www.bioconductor.org/packages...man/DESeq2.pdf

    library("phyloseq")
    library("ggplot2")
    library("devtools")
    otufile=("table.from_biom_w_consensuslineage_0_replaced.txt")
    mapfile=("Mapping_file_LS.txt")
    trefile=("rep_set_tree.tre")
    qiimedata = import_qiime(otufile, mapfile, trefile)

    qiimedata = subset_samples(qiimedata, LesionScore != "0")
    qiimedata = subset_samples(qiimedata, LesionScore != "1")
    qiimedata = subset_samples(qiimedata, LesionScore != "2")
    qiimedata = subset_samples(qiimedata, LesionScore != "3")

    diagdds = phyloseq_to_deseq2(qiimedata, ~ LesionScore)
    diagdds = DESeq(diagdds, test="Wald", fitType="parametric")

    res = results(diagdds, cooksCutoff = FALSE)
    alpha = 0.05
    sigtab = res[which(res$padj < alpha), ]
    sigtab = cbind(as(sigtab, "data.frame"), as(tax_table(qiimedata)[rownames(sigtab), ], "matrix"))
    head(sigtab)
    sigtabOrdered <- sigtab[order(sigtab$padj),]
    plotMA(res)
    plotDispEsts(diagdds)


    Any help would be great
    Sarah
    Last edited by sarah_27_m; 01-06-2017, 06:54 AM.
  • sarah_27_m
    Junior Member
    • Jan 2017
    • 4

    #2
    The answer to part of my question, this demonstrates that microbiome count data from amplicon sequencing experiments can be treated with the same procedures as for differential expression data from RNA-Seq experiments.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 12:17 PM
    0 responses
    14 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    15 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    37 views
    0 reactions
    Last Post SEQadmin2  
    Working...